William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty

uniQure N.V. (NASDAQ:QURE) ranks among the most oversold biotech stocks to invest in. William Blair reaffirmed its Market Perform rating for uniQure N.V. (NASDAQ:QURE) on November 11 while the company anticipates comments from regulators regarding its AMT-130 therapy. William Blair suggests that lobbyists and the medical community might put pressure on regulators to negotiate a quick route to BLA submission, citing the strong clinical results released last month and the early interest from patients and physicians for the Huntington’s disease medication.

The rating comes at a time when uniQure N.V. (NASDAQ:QURE) is dealing with serious AMT-130 regulatory issues. The results from uniQure’s Phase 1/2 studies, which were previously thought to be acceptable for a Biologics License Application (BLA), are no longer regarded as sufficient by the U.S. Food and Drug Administration (FDA).

uniQure N.V. (NASDAQ:QURE) anticipates receiving final minutes within 30 days from the pre-BLA meeting and intends to proactively engage with the FDA to find an approach toward the accelerated approval of AMT-130.

uniQure N.V. (NASDAQ:QURE) specializes in gene therapy by developing one-time gene therapies aimed at potentially curing genetic and serious diseases.

While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.